Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PN-881 Oral Solution
PN-881 · 1 trial · 1 indication
Evaluate the safety and tolerability of PN-881 in comparison to placebo after single and multiple doses in healthy subjects assessed for severity, seriousness, and relation to the investigational product.
| Arm | Type | Description |
|---|---|---|
| PN-881 Oral Solution Single Ascending Dose | EXPERIMENTAL | PN-881 Oral Solution Single Ascending Dose |
| Placebo Oral Solution Single Ascending Dose | PLACEBO_COMPARATOR | Placebo single ascending doses |
| PN-881 Oral Solution Multiple Ascending Dose | EXPERIMENTAL | PN-881 Multiple Ascending Doses |
| Placebo Oral Solution Multiple Ascending Dose | PLACEBO_COMPARATOR | Placebo, multiple ascending doses |
| PN-881 Oral Tablet Single Dose | EXPERIMENTAL | PN-881 oral tablet single dose |
| PN-881 Oral Tablet Multiple Dose | EXPERIMENTAL | PN-881 oral tablet multiple dose |
| Name | Type | Description |
|---|---|---|
| PN-881 Oral Solution | DRUG | PN-881 Oral Solution |
| PN-881 Oral Tablet | DRUG | PN-881 oral tablet |
| Placebo | DRUG | Placebo |
Inclusion Criteria: 1. Healthy male and female participants of non-childbearing potential, aged 18-65 years inclusive 2. Body mass index (BMI) between 18 and 32 kg/m² (inclusive) at screening 3. Willing and able to comply with all study requirements and provide written informed consent 4. Male part...
PN-881 is an investigational small molecule drug developed by Protagonist Therapeutics, Inc. It is an orally administered compound, also referred to as PN-881 Oral Solution, and has been studied in a Phase 1 clinical trial in healthy volunteers. Its therapeutic indications have not been disclosed.
PN-881 targets IL-17, a cytokine. As a small molecule directed at this cytokine target, it is being developed as an oral therapy. The IL-17 pathway is the molecular target named for this investigational compound.
PN-881 is developed by Protagonist Therapeutics, Inc., which trades under the ticker PTGX. The company is the sponsor of the clinical program for this oral small molecule.
PN-881 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this drug.
PN-881 has been evaluated in a single Phase 1 trial, NCT07153146, titled Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects. The trial was completed, enrolled 146 participants, was randomized, double-blind, and placebo-controlled, and was conducted in Australia.
Yes, PN-881 Oral Solution is another name for PN-881. Both refer to the same investigational small molecule developed by Protagonist Therapeutics, Inc.